Scientists track how new antibiotic zidebactam exits the body

NCT ID NCT07247942

Completed Knowledge-focused Sponsor: Wockhardt Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 study looked at how healthy men process and eliminate the antibiotic zidebactam. Eight participants received a single dose with a radioactive tracer to track the drug in urine and feces. The goal was to understand how the drug is broken down and how quickly it leaves the body, which helps guide future dosing studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: zidebactam (an antibiotic)
What this could lead to: If successful, this study will clarify how zidebactam is broken down and removed from the body, helping to design better dosing for future patients.
What could go wrong: This is a very early, small study in just 8 healthy men. It does not test whether the drug works against infections, and results may not apply to women or sick people.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS (HS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY SUBJECTS (HS)

Contacts and locations

Locations

Covance Clinical Research Unit Inc. 3402 Kinsman Boulevard Madison, Wisconsin 53704 USA

Madison, Wisconsin, 53704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.